An Integrated Study to Extrapolate the Interaction of NMDAR with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms

Year : 2023 | Volume : 01 | Issue : 01 | Page : 15-27
    By

    Varsini S.R.,

  • Samiksha Shivaji Bhor,

  1. Student, Department o Biotechnology, School of Bio-science and Technology, VIT University, Vellore, Tamil Nadu, India
  2. Bioinformatics Associate, Department of Biotechnology BioNome, Bengaluru, Karnataka, India

Abstract

Objective: Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting the health status of older adults especially those above the age of 60 years. As an outcome, two types of medications have been developed for the treatment of its symptoms which are acetylcholinesterase (AChE) and N-methyl-D-aspartate receptor (NMDAR) antagonist. This paper uses the computational approach to understand the interaction of NMDAR with four major phytocompounds (curcumin, L-epicatechin, ginsenosides, and resveratrol) by molecular docking NMDAR against the ligands. Then their therapeutic analysis and pharmacological characteristics were investigated.Method: In this study, the target protein NMDAR was retrieved from PDB and docked against six phytocompounds via PyRx. The binding affinity of the target protein with each ligand was compared and analyzed. Out of the six phytocompounds the top 4 phytocompounds were selected based on their binding affinity, which had to be lower than six. The top 4 were then studied using ADMET and visualized using BIOVIA Discovery Studio Visualizer. Results: Molecular docking results of the target protein, NMDAR, with the top 4 ligands (curcumin, L-epicatechin, ginsenosides, and resveratrol) showed that these ligands have the best binding affinity with the target protein. Conclusion: By analyzing the results, it can be concluded that the top 4 ligands (curcumin, L-epicatechin, ginsenosides, and resveratrol) can be used for the treatment of AD symptoms. However, ligands in vitro and in vivo studies must be carried out to understand the practical use of these ligands.

Keywords: Alzheimer’s disease (AD), N-methyl-D-aspartate receptor (NMDAR), curcumin, L-epicatechin, ginsenosides, resveratrol, molecular docking, ADMET

[This article belongs to International Journal of Biochemistry and Biomolecule Research ]

How to cite this article:
Varsini S.R., Samiksha Shivaji Bhor. An Integrated Study to Extrapolate the Interaction of NMDAR with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms. International Journal of Biochemistry and Biomolecule Research. 2023; 01(01):15-27.
How to cite this URL:
Varsini S.R., Samiksha Shivaji Bhor. An Integrated Study to Extrapolate the Interaction of NMDAR with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms. International Journal of Biochemistry and Biomolecule Research. 2023; 01(01):15-27. Available from: https://journals.stmjournals.com/ijbbr/article=2023/view=107326


Browse Figures

References

1. Monica Moore M, Díaz-Santos M, Vossel K, Alzheimer’s Association. Facts and figures report. Alzheimer’s Association; 2021.
2. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: an overview. Ann Indian Acad Neurol. 2008;11(1):13–9. doi: 10.4103/0972–2327.40220.
3. Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dial Clin Neurosci. 2000;2(3):219–32. doi: 10.31887/DCNS.2000.2.3/jnewcomer.
4. Cascella M, Bimonte S, Muzio MR, Schiavone V, Cuomo A. The efficacy of epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice. Infect Agents Cancer. 2017;12(1):36. doi: 10.1186/s13027–017–0145–6.
5. Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med. 2010;5(1):13. doi: 10.1186/1749–8546–5–13.
6. Ide K, Matsuoka N, Yamada H, Furushima D, Kawakami K. Effects of tea catechins on Alzheimer’s disease: recent updates and perspectives. Molecules. 2018;23(9):2357. doi: 10.3390/molecules23092357.
7. Lee YJ, Choi DY, Yun YP, Han SB, Oh KW, Hong JT. Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J Nutr Biochem. 2013;24(1):298–310. doi: 10.1016/j.jnutbio.2012.06.011.
8. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014;8:112. doi: 10.3389/fncel.2014.00112.
9. Wang N, Yang J, Chen R, Liu Y, Liu S, Pan Y et al. Ginsenoside Rg1 ameliorates Alzheimer’s disease pathology via restoring mitophagy. J Ginseng Res. 2023;47(3):448–57. doi: 10.1016/j.jgr.2022.12.001.
10. Al-Bishri WM, Hamza AH, Farran SK. Resveratrol Treatment Attenuates amyloid beta, Tau protein and Markers of Oxidative Stress, and Inflammation in Alzheimer’s disease Rat Model. Int J Pharm Res Allied Sci. 2017;6(3).
11. Rahman MH, Akter R, Bhattacharya T, Abdel-Daim MM, Alkahtani S, Arafah MW et al. Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer’s disease. Front Pharmacol. 2020;11:619024. doi: 10.3389/fphar.2020.619024.
12. Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17. doi: 10.1016/S0140–6736(15)01124–1.
13. Bye LJ, Finol-Urdaneta RK, Tae HS, Adams DJ. Nicotinic acetylcholine receptors: key targets for attenuating neurodegenerative diseases. Int J Biochem Cell Biol. 2023;157:106387. doi: 10.1016/j.biocel.2023.106387.
14. Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM. Multi-target drug candidates for multifactorial Alzheimer’s disease: AChE and NMDAR as molecular targets. Mol Neurobiol. 2021;58(1):281–303. doi: 10.1007/s12035–020–02116–9.
15. Danysz W, Parsons CG. Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine–searching for the connections. Br J Pharmacol. 2012;167(2):324–52. doi: 10.1111/j.1476–5381.2012.02057.x.
16. Cohen SM, Ma H, Kuchibhotla KV, Watson BO, Buzsáki G, Froemke RC. Excitation–inhibition imbalance leads to hippocampal hyperexcitability and impaired cognition in a mouse model of Alzheimer’s disease. Neuron. 2015;83(6):1382–93.
17. Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014;82(2):279–93. doi: 10.1016/j.neuron.2014.03.030.
18. Feng T, Wei Y, Lee RJ, Zhao L, Yu SP. The role of TRPM7 channels in neuronal cell apoptosis and necrosis. Brain Res Bull. 2019;151:151–8.
19. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005;25(38):8807–14. doi: 10.1523/JNEUROSCI.1521–05.2005.
20. Li QS, Li XY, Duan XL, Yang Y, Liu F, Yuan YH et al. Epigallocatechin‐3‐gallate attenuates cognitive deterioration in Alzheimer’s disease model mice by upregulating neprilysin expression. Exp Cell Res. 2013;319(5):704–13.
21. Jia JP, Li X, Li YJ. Ginsenoside Rg1 enhances NMDA receptor-mediated synaptic transmission in hippocampal CA1 area of rats. Sheng Li Xue Bao: [Acta Physiol Sin]. 2004;56(2):139–44.
22. Jang HJ, Nam JH, Oh JH, Lee JH, Kim JK. Ginsenoside Rb1 enhances N-methyl-D-aspartate receptor-mediated long-term potentiation and improves memory performance in aged rats. Physiol Behav. 2015;147:183–91.
23. Chen C, Yu R, Owuor ED, Kong AN. Activation of Nrf2/ARE pathway by resveratrol protects against oxidative stress-induced neuronal cell death in NSC-34 cells. Mol Cell Biochem. 2011;357(1–2):241–51.
24. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism. J Biol Chem. 2010;285(12):9100–13. doi: 10.1074/jbc.M109.060061.

Regular Issue Subscription Original Research
Volume 01
Issue 01
Received 13/04/2023
Accepted 29/04/2023
Published 10/05/2023
Publication Time 27 Days
Total Visits: 641


My IP

PlumX Metrics